File Download

There are no files associated with this item.

Supplementary

Conference Paper: Gut microbiota predicts treatment response to empagliflozin among metabolic dysfunction-associated steatotic liver disease (MASLD) patients without diabetes mellitus.

TitleGut microbiota predicts treatment response to empagliflozin among metabolic dysfunction-associated steatotic liver disease (MASLD) patients without diabetes mellitus.
Authors
Ng, HYZhang, LTan, JTHui, RWHLeung, WKYuen, MFSeto, WKCheung, KS.
Issue Date30-Nov-2024
Persistent Identifierhttp://hdl.handle.net/10722/360568

 

DC FieldValueLanguage
dc.contributor.authorNg, HY-
dc.contributor.authorZhang, L-
dc.contributor.authorTan, JT-
dc.contributor.authorHui, RWH-
dc.contributor.authorLeung, WK-
dc.contributor.authorYuen, MF-
dc.contributor.authorSeto, WK-
dc.contributor.authorCheung, KS.-
dc.date.accessioned2025-09-12T00:37:29Z-
dc.date.available2025-09-12T00:37:29Z-
dc.date.issued2024-11-30-
dc.identifier.urihttp://hdl.handle.net/10722/360568-
dc.languageeng-
dc.relation.ispartof30th Medical Research Conference (30/11/2024-30/11/2024)-
dc.titleGut microbiota predicts treatment response to empagliflozin among metabolic dysfunction-associated steatotic liver disease (MASLD) patients without diabetes mellitus.-
dc.typeConference_Paper-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats